Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

A new non-opioid painkiller, JournaVX, has received approval from the FDA, marking the first new type of pain medication in ...

Experts said millions of people across the country are prescribed a medicine for moderate to severe acute pain each year, so ...

The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid ...

The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...